{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T19:13:35Z","timestamp":1781982815085,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01375-w","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:18:53Z","timestamp":1760613533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9132","authenticated-orcid":false,"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2952","authenticated-orcid":false,"given":"Matthew J.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay She","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-2424","authenticated-orcid":false,"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0949","authenticated-orcid":false,"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353. Blood. 2023;141(4):437.","journal-title":"Blood"},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ajcp\/aqw214","volume":"147","author":"Y Natkunam","year":"2017","unstructured":"Natkunam Y, Goodlad JR, Chadburn A, de Jong D, Gratzinger D, Chan JK, et al. EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH\/EAHP Workshop Report-Part 1. Am J Clin Pathol. 2017;147:129\u201352.","journal-title":"Am J Clin Pathol"},{"key":"1375_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00428-022-03414-4","volume":"482","author":"L Quintanilla-Martinez","year":"2023","unstructured":"Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482:227\u201344.","journal-title":"Virchows Arch"},{"key":"1375_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/bjh.18763","volume":"201","author":"SA Atallah-Yunes","year":"2023","unstructured":"Atallah-Yunes SA, Salman O, Robertson MJ. Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies. Br J Haematol. 2023;201:383\u201395.","journal-title":"Br J Haematol"},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","volume":"378","author":"D Dierickx","year":"2018","unstructured":"Dierickx D, Habermann TM. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018;378:549\u201362.","journal-title":"N Engl J Med"},{"key":"1375_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196\u2013206.","journal-title":"Lancet Oncol"},{"key":"1375_CR7","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","volume":"36","author":"H Zimmermann","year":"2022","unstructured":"Zimmermann H, Koenecke C, Dreyling MH, Pott C, D\u00fchrsen U, Hahn D, et al. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia. 2022;36:2468\u201378.","journal-title":"Leukemia"},{"key":"1375_CR8","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","volume":"132","author":"Y Natkunam","year":"2018","unstructured":"Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JKC, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. Blood. 2018;132:1871\u20138.","journal-title":"Blood"},{"key":"1375_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ejh.12116","volume":"91","author":"A Ichikawa","year":"2013","unstructured":"Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20\u20138.","journal-title":"Eur J Haematol"},{"key":"1375_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","volume":"43","author":"D Kurita","year":"2019","unstructured":"Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors. Am J Surg Pathol. 2019;43:869\u201384.","journal-title":"Am J Surg Pathol"},{"key":"1375_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3899\/jrheum.130270","volume":"41","author":"N Yamakawa","year":"2014","unstructured":"Yamakawa N, Fujimoto M, Kawabata D, Terao C, Nishikori M, Nakashima R, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014;41:293\u20139.","journal-title":"J Rheumatol"},{"key":"1375_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.canep.2015.08.015","volume":"39","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015;39:1103\u201312.","journal-title":"Cancer Epidemiol"},{"key":"1375_CR13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684\u201392.","journal-title":"Br J Cancer"},{"key":"1375_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00930-7","volume":"13","author":"J Jelicic","year":"2023","unstructured":"Jelicic J, Juul-Jensen K, Bukumiric Z, Roost Clausen M, Ludvigsen Al-Mashhadi A, Pedersen RS, et al. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J. 2023;13:157.","journal-title":"Blood Cancer J"},{"key":"1375_CR15","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood.2023020779","volume":"144","author":"A Dabrowska-Iwanicka","year":"2024","unstructured":"Dabrowska-Iwanicka A, Nowakowski GS. DLBCL: who is high risk and how should treatment be optimized?. Blood. 2024;144:2573\u201382.","journal-title":"Blood"},{"key":"1375_CR16","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/ajt.12211","volume":"13","author":"AM Evens","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transpl. 2013;13:1512\u201322.","journal-title":"Am J Transpl"},{"key":"1375_CR17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1034\/j.1600-6143.2002.21011.x","volume":"2","author":"DE Tsai","year":"2002","unstructured":"Tsai DE, Nearey M, Hardy CL, Tomaszewski JE, Kotloff RM, Grossman RA, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transpl. 2002;2:946\u201354.","journal-title":"Am J Transpl"},{"key":"1375_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1128\/CMR.00006-09","volume":"23","author":"ML Gulley","year":"2010","unstructured":"Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23:350\u201366.","journal-title":"Clin Microbiol Rev"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01375-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:18:54Z","timestamp":1760613534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01375-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TMH:Data Monitoring Committee-Eli Lilly. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the May Clinic Institutional Review Board. The study was conducted in compliance with the Declaration of Helsinki. Given the retrospective nature of the study, a waiver of consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"163"}}